切换至 "中华医学电子期刊资源库"
高级检索
中华临床实验室管理电子杂志

中华临床实验室管理电子杂志 ›› 2021, Vol. 09 ›› Issue (02) : 99 -104. doi: 10.3877/cma.j.issn.2095-5820.2021.02.008

所属专题： 文献；

大数据分析

多数据库分析HELQ基因在肾透明细胞癌中的表达及临床应用价值
何晓慧1, 罗芳2, 王海龙3, 刘昭廷2,†()   
  1. 1. 510515　广东广州，南方医科大学发育生物学教研室；201210　上海，上海科技大学生命科学与技术学院
    2. 510515　广东广州，南方医科大学发育生物学教研室
    3. 510182　广东广州，广州医科大学金域检验学院
  • 收稿日期:2020-12-17 出版日期:2021-05-28
  • 通信作者: 刘昭廷

Multi-database analysis of HELQ expression in renal clear cell carcinoma and its clinical application value

Xiaohui He1, Fang Luo2, Hailong Wang3, Zhaoting Liu2,†()   

  1. 1. Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou Guangdong 510515, China; School of life science and technology, Shanghaitech University, Shanghai 201210, China
    2. Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou Guangdong 510515, China
    3. Kingmed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou Guangdong 510182, China
  • Received:2020-12-17 Published:2021-05-28
  • Corresponding author: Zhaoting Liu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

何晓慧, 罗芳, 王海龙, 刘昭廷. 多数据库分析HELQ基因在肾透明细胞癌中的表达及临床应用价值[J]. 中华临床实验室管理电子杂志, 2021, 09(02): 99-104.

Xiaohui He, Fang Luo, Hailong Wang, Zhaoting Liu. Multi-database analysis of HELQ expression in renal clear cell carcinoma and its clinical application value[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2021, 09(02): 99-104.

目的

探索HELQ及同源重组通路相关基因在肾透明细胞癌中的表达情况及对患者生存的影响。

方法

采用GEPIA和UALCAN网站分析HELQ mRNA在肾透明细胞癌及正常肾组织中的表达情况；利用R2网站分析HELQ mRNA表达量与肾透明细胞癌分级的关系；通过LinkedOmics和R2网站分析HELQ mRNA表达量与肾透明细胞癌TNM分期之间的关系；选择UALCAN，Kaplan-Meier Plotter，OncoLnc网站分析HELQ mRNA表达水平对肾透明细胞癌患者的生存影响；并利用R2网站分析同源重组通路相关基因对肾透明细胞癌患者的生存影响。

结果

肾透明细胞癌中的HELQ mRNA表达量低于正常肾组织(P＜0.01)；HELQ mRNA表达量随着肾透明细胞癌分级(P＜0.01)、分期增加有降低的趋势。发生淋巴结转移和远处转移的肾透明细胞癌患者的HELQ mRNA表达水平低于未发生淋巴结转移和远处转移患者，差异具有统计学意义(P＜0.01)；HELQ mRNA表达量与肾透明细胞癌患者的预后呈正相关(P＜0.01)。同源重组通路有21个基因表达量对肾透明细胞癌患者的生存也存在影响。

结论

HELQ可能与肾透明细胞癌的发生发展有关系。

关键词: HELQ, 肾透明细胞癌, 预后, 网站分析
Objective

To investigate the expression of HELQ and homologous reconbination pathway related genes in renal clear cell carcinoma (ccRCC) and the effect on patients' survival.

Methods

Expression of HELQ mRNA in ccRCC and normal samples were determined by websites of GEPIA and UALCAN. R2 website was used to analyze the relationship between the expression of HELQ mRNA and the grade of renal clear cell carcinoma. The relationship between HELQ mRNA expression and TNM staging was investigated by LinkedOmics and R2. We also used UALCAN, Kaplan-Meier Plotter, OncoLnc to detect the expression of HELQ mRNA on ccRCC patients' survival. Finally, we explored the expression of genes in homologous recombination pathway on ccRCC patients' survival. R2 website was used to analyze the survival effect of homologous recombination pathway related genes on patients with renal clear cell carcinoma.

Results

Compared to normal renal tissues, expression of HELQ was lower in clear cell renal cell carcinoma (P＜0.01). Expression of HELQ tended to decrease with grades (P＜0.01) and the stages of renal clear cell cell carcinoma. Besides patients with lymphatic metastasis and distant metastasis had lower HELQ mRNA expression (P＜0.01). Expression of HELQ was positively correlated with patients' survival (P＜0.01). The expression of 21 genes in homologous recombination pathway also influenced ccRCC patients' survival.

Conclusion

HELQ may have relationship with the development of renal clear cell cell carcinoma.

Key words: HELQ, Clear cell renal cell carcinoma, Prognosis, Website analysis
图1 HELQ在ccRCC和正常肾组织HELQ mRNA的表达情况
图2 HELQ mRNA表达水平与ccRCC分级的关系。
图3 HELQ mRNA与ccRCC TNM分期之间的关系。3a，3b，3c为HELQ分析结果，来自LinkedOmics数据库。
图4 HELQ mRNA表达水平与ccRCC患者的生存期的关系。
表1 同源重组通路基因对ccRCC患者的生存影响
同源重组修复通路基因(来自KEGG)

P 值

(高表达vs低表达)

 短生存期患者表达水平(相对于正常人)
EME1 P＜0.01 高
RAD54L P＜0.01 高
XRCC3 P＜0.01 高
RAD51 P＜0.01 高
TOP3B P＜0.01 高
POLD1 P＜0.01 高
BLM P＜0.01 高
RAD52 P＜0.01 高
RAD51B P＜0.01 高
POLD4 P＜0.01 高
MUS81 P＜0.01 高
XRCC2 P＜0.01 高
RAD54B P＜0.01 高
SHFM1 P＜0.01 高
RAD51D P＜0.01 高
TOP3A P＜0.01 高
RPA4 P＜0.05 高
POLD3 P＜0.05 高
RPA1 P＜0.01 低
SYCP3 P＜0.01 低
RAD50 P＜0.01 低
1
Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 317009.
2
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma[J]. Nature, 2013, 499(7456): 43-49.
3
Trivedi R, Dihazi GH, Eltoweissy M, et al. The antioxidant protein PARK7 plays an important role in cell resistance to Cisplatin-induced apoptosis in case of clear cell renal cell carcinoma[J]. Eur J Pharmacol, 2016, 78499-110.
4
Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma[J]. N Engl J Med, 2017, 376(4): 354-366.
5
Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[J]. Science, 2018, 359(6377):801-806.
6
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813.
7
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2): 125-134.
8
Harmon CS, DePrimo SE, Figlin RA, et al. Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-naive patients with metastatic renal cell carcinoma[J]. Cancer Chemother Pharmacol, 2014, 73(1): 151-161.
9
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase Ⅲ trial[J]. Lancet, 2008, 372(9637): 449-456.
10
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med, 2007, 356(22): 2271-2281.
11
Parikh M, JrLara PN. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type[J]. Annu Rev Med, 2018, 69209-221.
12
Marini F, Kim N, Schuffert A, et al. POLN, a nuclear PolA family DNA polymerase homologous to the DNA cross-link sensitivity protein Mus308[J]. J Biol Chem, 2003, 278(34): 32014-32019.
13
Han X, Zhao L, Li X. HELQ in cancer and reproduction[J]. Neoplasma, 2016, 63(6): 825-835.
14
Adelman CA, Lolo RL, Birkbak NJ, et al. HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis[J]. Nature, 2013, 502(7471): 381-384.
15
Liu DN, Zhou YF, Peng AF, et al. HELQ reverses the malignant phenotype of osteosarcoma cells via CHK1-RAD51 signaling pathway[J]. Oncol Rep, 2017, 37(2): 1107-1113.
16
Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
17
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses[J]. Neoplasia, 2017, 19(8): 649-658.
18
Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46(1):956-963.
19
Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma[J]. R Soc Open Sci, 2018, 5(12): 181006.
20
Dagher J, Delahunt B, Rioux-Leclercq N, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading[J]. Histopathology, 2017, 71(6): 918-925.
21
Piazza A, Heyer WD. Homologous Recombination and the Formation of Complex Genomic Rearrangements[J]. Trends Cell Biol, 2019, 29(2): 135-149.
22
Mouw KW, Goldberg MS, Konstantinopoulos PA, et al. DNA Damage and Repair Biomarkers of Immunotherapy Response[J]. Cancer Discov, 2017, 7(7): 675-693.
23
O'Connor MJ. Targeting the DNA Damage Response in Cancer[J]. Mol Cell, 2015, 60(4): 547-560.
[1] 张卫平, 王婧玲, 刘志兴, 陈莉, 谌芳群. 肾透明细胞癌高帧频超声造影时间-强度曲线特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 916-922.
[2] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[3] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[4] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[5] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[6] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[7] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[8] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[9] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[10] 张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[11] 张维志, 刘连新. 基于生物信息学分析IPO7在肝癌中的表达及意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 694-701.
[12] 叶文涛, 吴忠均, 廖锐. 癌旁组织ALOX15表达与肝癌根治性切除术后预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 708-712.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号